Overview
- This new text book on bladder cancer gives both the clinicians and laboratory investigators state-of-the art information on basic science and clinical aspects of bladder cancer.
Part of the book series: Cancer Drug Discovery and Development (CDD&D)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (22 chapters)
-
Front Matter
Keywords
About this book
Bladder cancer is a common cancer of the urinary tract. It is the fourth leading cause of cancer-related death among men and the seventh among women. Clinical management of bladder cancer is challenging because of the heterogeneity among bladder tumors with respect to invasion and metastasis, frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treatments and poor prognosis of patients with tumors that invade the bladder muscle and beyond. Due to these factors it has been said that the cost per patient of bladder cancer, from diagnosis to death is the highest of all cancers. In addition to it being a significant health problem, bladder cancer is an interesting cancer to study in many ways than one. For example, Environmental factors such as cigarette smoking and other carcinogens play a major role in the development of transitional carcinoma of the bladder, whereas, schitosomasis, a protozoan infection results in squamous cell carcinoma of the bladder. Different molecular pathways with distinct molecular signatures appear to be involved in the development of low-grade versus high-grade bladder tumors. Currently being monitored by an invasive endoscopic procedure, cystectomy, with urine cytology as an adjunct, bladder cancer is at the forefront of developing cancer biomarkers for non-invasive detection. Due to the differences in the invasive and metastatic potential of bladder tumors, treatment options differ depending upon tumor grade and stage. New advances are being made in treatment options to improve the outcome and quality of life for patients with bladder cancer. Similarly, new molecular nomograms are being discovered to predict treatment outcome so that individualized treatment options can be offered to patients.
Reviews
From the reviews:
“In this comprehensive review of all aspects of bladder cancer, 22 chapters are written by an international mix of clinicians and basic scientists. … This book is designed to be helpful to both clinicians and basic scientists. … The book accomplishes its goal as a broad but concise overview of all aspects of bladder cancer. … this is an effective textbook for a variety of audiences.” (Edouard Trabulsi, Doody’s Review Service, July, 2011)
“Editors Vinata Lokeshwar, Axel Merseburger and Stefan Hautmann and 40 contributors, all worldwide experts, collaborated on this textbook dedicated to various aspects of bladder cancer. The aim was to provide the reader with exhaustive information on current advances in all fields of bladder cancer. … This excellent textbook covers all topics related to bladder cancers and the authors reached their ambitious objective. All physicians and researchers involved in bladder cancer will be grateful to the authors for this useful reference.” (European Urology Today, July/August, 2011)
Editors and Affiliations
Bibliographic Information
Book Title: Bladder Tumors:
Book Subtitle: Molecular Aspects and Clinical Management
Editors: Vinata B. Lokeshwar, Axel S. Merseburger, Stefan H. Hautmann
Series Title: Cancer Drug Discovery and Development
DOI: https://doi.org/10.1007/978-1-60761-928-4
Publisher: Humana Totowa, NJ
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer Science+Business Media, LLC 2011
Hardcover ISBN: 978-1-60761-927-7Published: 02 December 2010
Softcover ISBN: 978-1-61779-719-4Published: 25 January 2013
eBook ISBN: 978-1-60761-928-4Published: 16 December 2010
Series ISSN: 2196-9906
Series E-ISSN: 2196-9914
Edition Number: 1
Number of Pages: XVI, 468
Topics: Cancer Research, Pharmacology/Toxicology